KR101459613B1 - Soybean Paste and Manufacturing Method There of - Google Patents
Soybean Paste and Manufacturing Method There of Download PDFInfo
- Publication number
- KR101459613B1 KR101459613B1 KR1020120068425A KR20120068425A KR101459613B1 KR 101459613 B1 KR101459613 B1 KR 101459613B1 KR 1020120068425 A KR1020120068425 A KR 1020120068425A KR 20120068425 A KR20120068425 A KR 20120068425A KR 101459613 B1 KR101459613 B1 KR 101459613B1
- Authority
- KR
- South Korea
- Prior art keywords
- rice
- meju
- aging
- present
- doenjang
- Prior art date
Links
- 235000010469 Glycine max Nutrition 0.000 title claims abstract description 27
- 244000068988 Glycine max Species 0.000 title claims abstract description 27
- 238000004519 manufacturing process Methods 0.000 title abstract description 19
- 235000007164 Oryza sativa Nutrition 0.000 claims abstract description 119
- 235000009566 rice Nutrition 0.000 claims abstract description 119
- 238000000034 method Methods 0.000 claims abstract description 30
- 230000032683 aging Effects 0.000 claims abstract description 23
- 230000001093 anti-cancer Effects 0.000 claims abstract description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 150000003839 salts Chemical class 0.000 claims abstract description 16
- 238000002156 mixing Methods 0.000 claims abstract description 10
- 230000001747 exhibiting effect Effects 0.000 claims abstract description 5
- 241000209094 Oryza Species 0.000 claims abstract 9
- 239000000203 mixture Substances 0.000 claims description 36
- 244000294411 Mirabilis expansa Species 0.000 claims description 24
- 235000015429 Mirabilis expansa Nutrition 0.000 claims description 24
- 235000013536 miso Nutrition 0.000 claims description 24
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 13
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 13
- 244000063299 Bacillus subtilis Species 0.000 claims description 9
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 7
- 241000228212 Aspergillus Species 0.000 claims description 4
- 238000000465 moulding Methods 0.000 claims description 4
- 241000272525 Anas platyrhynchos Species 0.000 claims description 3
- 235000013339 cereals Nutrition 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 abstract description 9
- 244000005700 microbiome Species 0.000 abstract description 8
- 230000008901 benefit Effects 0.000 abstract description 6
- 240000007594 Oryza sativa Species 0.000 description 110
- 239000000284 extract Substances 0.000 description 28
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 24
- 238000009472 formulation Methods 0.000 description 17
- 230000000694 effects Effects 0.000 description 15
- 238000000855 fermentation Methods 0.000 description 14
- 230000004151 fermentation Effects 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 239000004310 lactic acid Substances 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 11
- 230000008859 change Effects 0.000 description 11
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 235000014655 lactic acid Nutrition 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 10
- 229940024606 amino acid Drugs 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000000796 flavoring agent Substances 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 235000000346 sugar Nutrition 0.000 description 9
- 235000013305 food Nutrition 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 240000006439 Aspergillus oryzae Species 0.000 description 7
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 7
- 108091005804 Peptidases Proteins 0.000 description 7
- 239000004365 Protease Substances 0.000 description 7
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 7
- XKMRRTOUMJRJIA-UHFFFAOYSA-N ammonia nh3 Chemical compound N.N XKMRRTOUMJRJIA-UHFFFAOYSA-N 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 239000004382 Amylase Substances 0.000 description 5
- 102000013142 Amylases Human genes 0.000 description 5
- 108010065511 Amylases Proteins 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 238000000134 MTT assay Methods 0.000 description 5
- 231100000002 MTT assay Toxicity 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 235000019418 amylase Nutrition 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 102100030800 Ras suppressor protein 1 Human genes 0.000 description 4
- 101710102668 Ras suppressor protein 1 Proteins 0.000 description 4
- 235000010716 Vigna mungo Nutrition 0.000 description 4
- 235000011453 Vigna umbellata Nutrition 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Natural products OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- 240000001417 Vigna umbellata Species 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 230000005907 cancer growth Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000005070 ripening Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 235000013555 soy sauce Nutrition 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- 101000650776 Boana raniceps Raniseptin-2 Proteins 0.000 description 2
- 101000650777 Boana raniceps Raniseptin-3 Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 102000004139 alpha-Amylases Human genes 0.000 description 2
- 108090000637 alpha-Amylases Proteins 0.000 description 2
- 229940024171 alpha-amylase Drugs 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000001384 succinic acid Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- WDMUXYQIMRDWRC-UHFFFAOYSA-N 2-hydroxy-3,4-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C([N+]([O-])=O)=C1O WDMUXYQIMRDWRC-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- QISOBCMNUJQOJU-UHFFFAOYSA-N 4-bromo-1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1NN=CC=1Br QISOBCMNUJQOJU-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000228257 Aspergillus sp. Species 0.000 description 1
- 241000045403 Astragalus propinquus Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 229910019093 NaOCl Inorganic materials 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 239000006035 Tryptophane Substances 0.000 description 1
- 206010046431 Urethral cancer Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 244000042295 Vigna mungo Species 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- FHKPLLOSJHHKNU-INIZCTEOSA-N [(3S)-3-[8-(1-ethyl-5-methylpyrazol-4-yl)-9-methylpurin-6-yl]oxypyrrolidin-1-yl]-(oxan-4-yl)methanone Chemical compound C(C)N1N=CC(=C1C)C=1N(C2=NC=NC(=C2N=1)O[C@@H]1CN(CC1)C(=O)C1CCOCC1)C FHKPLLOSJHHKNU-INIZCTEOSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- SPBWMYPZWNFWES-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide;dihydrate Chemical compound O.O.[Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N SPBWMYPZWNFWES-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000010200 folin Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 235000021109 kimchi Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 208000011866 pituitary adenocarcinoma Diseases 0.000 description 1
- 239000001967 plate count agar Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 235000019643 salty taste Nutrition 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
- A23L11/50—Fermented pulses or legumes; Fermentation of pulses or legumes based on the addition of microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/104—Fermentation of farinaceous cereal or cereal material; Addition of enzymes or microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Agronomy & Crop Science (AREA)
- Botany (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 하기 단계를 포함하는 항암(抗癌) 활성을 나타내는 쌀된장 제조방법을 제공한다: (a) 증자(蒸煮)콩 및 쌀을 배합한 이후 미생물을 접종하는 단계: (b) 상기 단계 (a)의 미생물을 접종하여 배합한 증자콩 및 쌀을 이용하여 메주를 성형(成型)한 이후 숙성하는 단계: (c) 상기 단계(b)의 메주를 파쇄(破碎)하는 단계: 및 (d) 상기 단계(c)의 파쇄된 메주에 물 및 소금을 첨가한 이후 숙성하는 단계. 본 발명의 방법으로 제조한 쌀된장의 경우 탁월한 항암 효과를 나타내는 장점을 제공한다. 또한, 본 발명의 방법으로 제조한 쌀된장의 경우 기존 재래 된장과 비교하여, 유기산 등의 함량이 많을 뿐만 아니라, 제조 기간을 비약적으로 단축시킬 수 있는 장점을 제공한다.The present invention provides a method for preparing rice doenjang exhibiting anticancer activity comprising the steps of: (a) inoculating a microorganism after mixing the roasted soybean and rice; (b) (c) crushing the Meju of the step (b); and (d) digesting the Meju of the step (b) Adding water and salt to the crushed meju of step (c) and then aging. The rice doenjang produced by the method of the present invention provides an advantage of exhibiting excellent anticancer effect. In addition, in the case of rice doenjang produced by the method of the present invention, the content of organic acid and the like is much higher than that of conventional doenjang, and the manufacturing time is drastically shortened.
Description
본 발명은 암 세포주의 생장을 효과적으로 억제하고, 유산균의 증식에 필요한 영양 성분이 다량 함유되어 유산 발효가 잘 이루어지고 영양 성분이 고루 풍부하며 인체에 안전한 쌀된장의 제조방법에 관한 것이다.The present invention relates to a method for effectively preventing the growth of cancer cell lines, containing a large amount of nutritional components necessary for the growth of lactic acid bacteria, fermenting lactic acid well, having a rich nutritional content, and being safe to human body.
쌀은 탄수화물뿐만 아니라 단백질 공급원으로서도 중요한 역할을 한다. 쌀 단백질은 다른 곡류에 비해 함량은 적지만 필수 아미노산인 라이신이 옥수수. 밀가루보다 두 배나 많고 쌀 단백질은 체내 이용률이 높아 콜레스테롤이나 중성 지방의 농도를 낮춘다. 이 밖에도 쌀에는 엽산을 포함한 비타민 B군은 물론 비타민 E. 마그네슘 등이 풍부하다. 비타민 E 등은 강력한 항산화 작용을 하기 때문에 노화 방지에 효과가 있다. 그러나 최근 국민의 입맛 고급화, 건강식품 선호, 1인당 쌀 소비량 감소, 수입 개방 확대 등으로 쌀 소비는 감소하는데 공급이 과다해 재고가 증가하고 쌀값이 하락하여 곤란을 겪고 있다.Rice plays an important role as a protein source as well as carbohydrates. Rice protein is less in content than other grains, but lysine, which is an essential amino acid, is corn. It is twice as many as wheat flour and rice protein has a high rate of use, lowering the levels of cholesterol and triglycerides. In addition, rice is rich in vitamin E, as well as vitamin B, including folic acid. Vitamin E and other antioxidant effect is effective in preventing aging. However, recently, rice consumption has decreased due to higher taste of people, preference for healthy food, decrease in per capita rice consumption, and opening of imports. This is due to excessive supply of stocks and falling rice prices.
된장은 제조방식에 따라 메주로 담금하는 재래식 된장과 코오지로 담금하는 개량식 된장으로 대별된다. 재래식 된장은 메주에 번식한 각종 세균과 곰팡이가 생산하는 효소 작용으로, 코오지식은 아스퍼질러스 오리재(Aspergillus oryzae)가 생산하는 아밀라제(amylase), 프로테아제(protease) 등의 효소 작용으로 원료 성분인 콩을 분해하여 발효한다. 이때, 된장의 맛은 숙성과정 중 효소작용에 의해 콩 단백질로부터 생성된 아미노산에 의하여 제공되는 구수한 맛에 미량의 당분과 소금에 의한 단맛과 짠맛의 조화로 맛을 더하고, 이와 더불어 내염성 효모나 젖산균의 발효로 생성되는 풍미와 원료 그 자체나 미생물 발효에서 생성되는 색 등이 적절하게 조화를 이룸으로써 결정된다.Miso is divided into traditional miso soaked with meju and modified miso soaked with koji depending on the manufacturing method. Conventional doenjang is an enzyme produced by various bacteria and fungi that propagate in Meju, and Koyo is produced by the enzyme action of amylase and protease produced by Aspergillus oryzae. The soybean is decomposed and fermented. At this time, the flavor of doenjang is enhanced by the enzymatic action during the fermentation process, and the flavor is enhanced by the harmony of sweet taste and salty taste due to the small amount of sugar and salt and a slight taste provided by the amino acid produced from the soybean protein. In addition, The flavor produced by fermentation and the color produced by the raw material itself or microbial fermentation are determined by appropriately coordinating.
한편, 종래의 전통 된장은 식염 함량이 높고 색깔이 검고 콩에서 나는 불쾌취로 인해 신세대들로부터 기피하는 현상을 보이고 있다. 최근 장류가 항암 등 기능적인 효과가 알려지면서 기능적인 장류를 개발하려는 연구, 예를 들어 기능적인 성분과 된장을 혼합하는 등의 된장의 기능성을 향상시키려는 연구가 다양하게 수행되고 있다.On the other hand, conventional traditional doenjang shows a phenomenon of avoiding the new generation due to high salt content, black color, and unpleasant odor in the soybean. Recently, various studies have been conducted to improve functional properties of soybean paste such as functional soybean paste mixed with functional ingredient, for example, to develop functional soy sauce with functional effects such as anticancer.
KR 공개특허 10-2009-0064770(발명의 명칭 : 쌀된장의 제조 방법)에서는 쌀 및 콩에 누룩을 접종하는 단계를 포함하는 쌀된장 제조방법에 대해 개시하고 있고, KR 공개특허 10-2008-006902(발명의 명칭 : 쌀되장의 제조 방법)에서는 쌀 및 콩에 아스퍼질러스 오리재를 접종하는 단계를 포함하는 쌀된장 제조방법에 대해 개시하고 있다.KR Patent Application No. 10-2009-0064770 discloses a method for producing rice doenjang comprising the step of inoculating koji into rice and soybean, Discloses a process for producing rice doenjang comprising the step of inoculating rice and soybean with aspergillus ducks.
그러나 상술한 특허 문헌의 경우 얻어지는 된장의 기호성을 효과적으로 향상시키지 못하고, 항암 효과 등의 기능성도 부족한 문제가 존재한다.
However, in the case of the above-mentioned patent documents, there is a problem that the palatability of the soybean paste obtained can not be effectively improved and the functionalities such as anticancer effect are also insufficient.
본 명세서 전체에 걸쳐 다수의 논문 및 특허문헌이 참조되고 그 인용이 표시되어 있다. 인용된 논문 및 특허문헌의 개시 내용은 그 전체로서 본 명세서에 참조로 삽입되어 본 발명이 속하는 기술 분야의 수준 및 본 발명의 내용이 보다 명확하게 설명된다.Numerous papers and patent documents are referenced and cited throughout this specification. The disclosures of the cited papers and patent documents are incorporated herein by reference in their entirety to better understand the state of the art to which the present invention pertains and the content of the present invention.
본 발명자들은 제조공정이 단순하면서도, 항암효과 등 기능성이 우수한 전통 된장을 개발하기 위해서 예의 연구 노력하였다. 그 결과 증자콩 및 쌀에 스타터로서 바실러스 서브틸러스 및/또는 아스퍼질러스 오리재를 접종하여 된장을 제조할 경우 제조 기간을 비약적으로 단축시킬 수 있으면서, 항암효과가 매우 우수한 전통 된장을 제조할 수 있다는 사실을 발견하여 본 발명을 완성하였다.The inventors of the present invention have made extensive efforts to develop a conventional soy sauce having excellent functional properties such as anticancer effect while being simple in the manufacturing process. As a result, when soybean paste is prepared by inoculating Bacillus subtilis and / or Aspergillus oryzae as a starter to beef and soybean beans, it is possible to shorten the production period drastically, And have completed the present invention.
따라서 본 발명의 목적은 쌀된장 제조방법을 제공하는데 있다.Accordingly, an object of the present invention is to provide a method for manufacturing rice doenjang.
또한, 본 발명의 다른 목적은 상기 쌀된장 또는 상기 쌀된장 추출물을 포함하는 식품 또는 약제학적 조성물을 제공하는데 있다.
Another object of the present invention is to provide a food or pharmaceutical composition comprising the rice doenjang or the rice doenjang extract.
본 발명의 다른 목적 및 이점은 하기의 발명의 상세한 설명, 청구범위 및 도면에 의해 보다 명확하게 된다.Other objects and advantages of the present invention will become more apparent from the following detailed description of the invention, claims and drawings.
본 발명은 쌀된장 제조방법을 제공한다.The present invention provides a method for producing rice doenjang.
본 발명자들은 제조공정이 단순하면서도, 항암효과 등 기능성이 우수한 전통 된장을 개발하기 위해서 예의 연구 노력하였다. 그 결과 증자콩 및 쌀에 스타터로서 바실러스 서브틸러스 및/또는 아스퍼질러스 오리재를 접종하여 된장을 제조할 경우 제조 기간을 비약적으로 단축시킬 수 있으면서, 항암효과가 매우 우수한 전통 된장을 제조할 수 있다는 사실을 확인하였다.
The inventors of the present invention have made extensive efforts to develop a conventional soy sauce having excellent functional properties such as anticancer effect while being simple in the manufacturing process. As a result, when soybean paste is prepared by inoculating Bacillus subtilis and / or Aspergillus oryzae as a starter to beef and soybean beans, it is possible to shorten the production period drastically, .
본 발명의 일 양태에 따르면, 본 발명은 하기 단계를 포함하는 항암(抗癌) 활성을 나타내는 쌀된장 제조방법을 제공한다: (a) 증자(蒸煮)콩 및 쌀을 배합한 이후 미생물을 접종하는 단계: (b) 상기 단계 (a)의 미생물을 접종하여 배합한 증자콩 및 쌀을 이용하여 메주를 성형(成型)한 이후 숙성하는 단계: (c) 상기 단계(b)의 메주를 파쇄(破碎)하는 단계: 및 (d) 상기 단계(c)의 파쇄된 메주에 물 및 소금을 첨가한 이후 숙성하는 단계. According to one aspect of the present invention, the present invention provides a method for preparing rice doenjang exhibiting anticancer activity comprising the steps of: (a) cultivating soybeans and rice, (B) aging the meju after the meju is formed using the expanded beans and rice inoculated with the microorganism of step (a); (c) aging the meju of step (b) (D) adding water and salt to the crushed meju of step (c) and then aging.
본 명세서에서 용어 “항암”은 생체내 암세포 또는 암조직의 성장을 억제 또는 사멸하는 것을 의미한다. 예를 들면, 위암, 폐암, 유방암, 난소암, 간암, 직장암, 기관지암, 비인두암, 후두암, 췌장암, 방광암, 결장암, 자궁경부암, 자궁내막 암, 뇌암, 전립선암, 골암, 피부암, 갑상선암, 백혈병, non-Hodgkin 임파선암, 부갑상선암 및 요관암 세포 또는 조직을 포함하나, 이에 한정되는 것은 아니다. The term " anti-cancer " as used herein means inhibiting or killing the growth of cancer cells or cancer tissues in vivo. For example, there is provided a method of treating cancer, cancer, breast cancer, ovarian cancer, liver cancer, rectum cancer, bronchial cancer, , non-Hodgkin lymphoma, pituitary adenocarcinoma and urethral cancer cells or tissues.
본 발명의 바람직한 양태에 따르면, 상기 단계 (a)의 증자콩은 콩을 바람직하게는 1-48 시간, 가장 바람직하게는 20-30 시간 수침(水浸)한 이후 고압멸균기(autoclave)를 이용하여 증자하고, 마쇄(磨碎) 처리하는 단계를 포함하여 제조될 수 있다.According to a preferred embodiment of the present invention, the expanded beans of step (a) are prepared by soaking the soybeans for preferably 1-48 hours, most preferably 20-30 hours, followed by autoclaving And a step of grinding (grinding).
본 발명의 바람직한 양태에 따르면, 상기 고압멸균기의 온도 조건은 바람직하게는 80-150℃이고, 보다 바람직하게는 100-130℃이며, 가장 바람직하게는 115-130℃일 수 있다.According to a preferred embodiment of the present invention, the temperature condition of the high-pressure sterilizer is preferably 80-150 캜, more preferably 100-130 캜, and most preferably 115-130 캜.
본 발명의 바람직한 양태에 따르면, 상기 고압멸균기의 처리 시간은 바람직하게는 1-120분일 수 있고, 보다 바람직하게는 20-60분일 수 있으며, 가장 바람직하게는 305-45분일 수 있다.According to a preferred embodiment of the present invention, the treatment time of the high-pressure sterilizer may be preferably 1-120 minutes, more preferably 20-60 minutes, and most preferably 305-45 minutes.
본 발명의 바람직한 양태에 따르면, 상기 단계 (a)의 배합시 쌀 및 증자콩의 배합비율은 1:0.5-2일 수 있고, 가장 바람직하게는 1:1-1.5일 수 있다. 본 발명에서 가장 바람직한 쌀 및 증자콩의 배합 비율이 1-1.5인 이유는 쌀 및 증자콩의 배합 비율이 1:1 미만일 경우 발효 기간이 단축되지 않는 결과를 나타냈고, 배합 비율이 1:1.5를 초과하는 경우 항암 효과가 현저히 감소하였기 때문이다. 따라서 본 발명에서 상기 쌀 및 증자콩의 배합 비율은 매우 중요하다.According to a preferred embodiment of the present invention, when the step (a) is blended, the blending ratio of rice and expanded soybean may be 1: 0.5-2, and most preferably 1: 1-1.5. In the present invention, the most preferable ratio of the rice and the increased soybean is 1-1.5. The reason is that the fermentation period is not shortened when the blending ratio of rice and the soybean is less than 1: 1, and the blending ratio is 1: 1.5 The anticancer effect was significantly reduced. Therefore, in the present invention, the mixing ratio of the above rice and the abovementioned beans is very important.
본 발명의 바람직한 양태에 따르면, 상기 단계 (a)의 미생물은 바람직하게는 바실러스 서브틸러스(Bacillus subtillis) 또는 아스퍼질러스 오리재(Aspergillus oryzae)일 수 있다.According to a preferred embodiment of the present invention, the microorganism of step (a) is preferably Bacillus subtilis or Aspergillus oryzae.
또한, 경우에 따라서는 상기 바실러스 서브틸러스 및 상기 아스퍼질러스 오리재를 혼합하여 접종하거나, 또는 상기 증자콩에는 상기 바실러스 서브틸러스를 접종하고, 상기 쌀에는 상기 아스퍼질러스 오리재를 접종할 수 있다. In some cases, the Bacillus subtilis and the Aspergillus oryzae may be mixed and inoculated, or the Bacillus subtilis may be inoculated to the expanded beans, and the aspergillus duck material may be inoculated into the rice .
상기 바실러스 서브틸러스 및 상기 아스퍼질러스 오리재를 혼합하여 접종할 경우 각각의 미생물 단독으로 접종할 경우와 비교하여 항암 효과를 극대화할 수 있는 장점이 있고, 상기 증자콩에는 상기 바실러스 서브틸러스를 접종하고, 상기 쌀에는 상기 아스퍼질러스 오리재를 접종할 경우에는 유기산 함량을 증가시키고, 제조기간을 단축시킬 수 있는 장점이 있다. 따라서, 본 발명의 제조방법을 이용할 경우 쌀된장 제조 목적에 따라 미생물 접종방법 및 접종 미생물을 각기 달리할 수 있는 장점이 있다.When the Bacillus subtilis and the Aspergillus oryzae are mixed and inoculated, there is an advantage that the anticancer effect can be maximized as compared with the case of inoculation with each microorganism alone, and the Bacillus subtilis And when the aspergillus duck is inoculated into the rice, the organic acid content is increased and the production period is shortened. Therefore, when the production method of the present invention is used, there is an advantage that the microorganism inoculation method and inoculation microorganism can be different according to the purpose of producing rice miso.
본 발명의 바람직한 양태에 따르면, 상기 단계 (b)의 성형시 성형 형상은 무형상(낱알 형상 또는 홑임 메주), 육면체 형상 또는 디스크 형상일 수 있다.According to a preferred embodiment of the present invention, the forming shape in the molding of step (b) may be an intangible shape (grain shape or mezzanine shape), a hexahedron shape, or a disk shape.
본 발명의 바람직한 양태에 따르면, 상기 단계 (b)의 숙성시 숙성 기간은 1-30일이고, 숙성 온도는 25-35℃이며, 숙성 습도는 60-90%일 수 있다.According to a preferred embodiment of the present invention, the aging period of the step (b) is 1-30 days, the aging temperature is 25-35 ° C, and the aging humidity is 60-90%.
본 발명의 바람직한 양태에 따르면, 상기 단계 (d)의 소금 및 물의 배합 비율은 바람직하게는 1:5-10일 수 있고, 가장 바람직하게는 1:10 즉, 소금의 함량이 물 함량 대비 10% 내외일 수 있다. 본 발명에서 소금 및 물의 배합비율이 1:10 내외인 점은 통상적인 된장 제조과정에서 소금 함량이 15% 이상이라는 점에서 매우 중요하다.According to a preferred embodiment of the present invention, the mixing ratio of salt and water in step (d) may be preferably 1: 5-10, and most preferably 1:10. That is, the salt content is preferably 10% It can be inside or outside. In the present invention, the mixing ratio of salt and water is about 1:10, which is very important in that the salt content is 15% or more in the conventional process of making miso.
왜냐하면, 과도한 소금을 첨가할 경우 숙성 기간을 비약적으로 증가시킬 수 있고, 또한 고혈압 등 성인병을 유발할 수 있는 문제가 있으며, 소금 함량 감소에 따른 된장 부패 위험을 쌀 및 콩 등 최적 원재료 선택 및 최적 발효 조건 선택에 의해 방지하였기 때문이다. The reason for this is that the addition of excessive salt may drastically increase the ripening period and may cause an adult disease such as hypertension. In addition, the risk of the soybean spoilage due to the decrease of the salt content is selected by selecting the optimum raw materials such as rice and soybean, This is because it is prevented by selection.
본 발명의 바람직한 양태에 따르면, 상기 단계 (d)의 숙성시 숙성 기간은 바람직하게는 1-60일일 수 있고, 보다 바람직하게는 10-50일일 수 있으며, 가장 바람직하게는 35-45일일 수 있다.According to a preferred embodiment of the present invention, the aging period of the step (d) may preferably be 1-60 days, more preferably 10-50 days, and most preferably 35-45 days .
본 발명의 제조방법을 이용할 경우 메주 제조부터 숙성 단계까지 5개월의 기간이 소요되는 일반 된장과는 달리 약 6주만에 된장을 완성할 수 있는 장점을 제공한다.
Unlike general miso, which takes 5 months from meju production to aging, using the manufacturing method of the present invention provides a merit that can be completed in about 6 weeks.
본 발명의 다른 양태에 따르면, 본 발명은 상기 방법으로 제조된 살된장 추출물을 유효성분으로 포함하는 암 예방 또는 치료용 조성물을 제공한다.According to another aspect of the present invention, there is provided a composition for preventing or treating cancer comprising an extract of Salmon extract prepared by the above method as an active ingredient.
본 명세서에서의 용어 "예방"은 질환 또는 질병을 보유하고 있다고 진단된 적은 없으나, 이러한 질환 또는 질병에 걸리기 쉬운 경향이 있는 동물에서 질환 또는 질병의 발생을 억제하는 것을 의미할 수 있다. As used herein, the term "prevention" may mean inhibiting the occurrence of a disease or disease in an animal that has never been diagnosed as having a disease or condition, but tends to be susceptible to such disease or disease.
본 명세서에서 용어 “치료”는 (a) 질환 또는 질병의 발전의 억제; (b) 질환 또는 질병의 경감; 및 (c) 질환 또는 질환의 제거를 의미할 수 있다.As used herein, the term " treatment " means (a) inhibiting the development of a disease or disease; (b) relief of disease or disease; And (c) removal of the disease or disorder.
본 발명의 조성물은 유효성분으로 이용되는 쌀된장 추출물을 포함한다. 본 명세서에서 쌀된장을 언급하면서 사용되는 용어 “추출물”은 쌀된장에 추출용매를 처리하여 얻은 추출 결과물뿐만 아니라 쌀된장 자체를 동물에게 투여할 수 있도록 제형화(예컨대, 분말화)된 쌀된장 가공물도 포함하는 의미를 갖는다.The composition of the present invention includes rice doenjang extract used as an active ingredient. The term " extract " used herein to refer to rice miso is not limited to the extraction result obtained by treating the rice doenjang with the extraction solvent, but also the rice miso product (e.g., powdered rice miso product) . ≪ / RTI >
만일, 본 발명의 조성물에서 이용되는 쌀된장 추출물을 쌀된장에 추출용매를 처리하여 얻는 경우에는, 다양한 추출용매가 이용될 수 있다. 바람직하게는, (a) 물, (b) 탄소수 1-4의 무수 또는 함수 저급 알코올 (예: 메탄올, 에탄올, 프로판올, 부탄올, 노말-프로판올, 이소-프로판올 및 노말-부탄올 등), (c) 상기 저급 알코올과 물과의 혼합용매, (d) 아세톤, (e) 에틸 아세테이트, (f) 클로로포름, (g) 1,3-부틸렌글리콜, (h) 헥산, (i) 디에틸에테르, 또는 (j) 부틸아세테이트를 쌀된장에 처리하여 추출물을 얻을 수 있다. If the rice doenjang extract used in the composition of the present invention is obtained by treating the rice doenjang with an extraction solvent, various extraction solvents may be used. (B) an anhydrous or a lower alcohol having 1 to 4 carbon atoms such as methanol, ethanol, propanol, butanol, n-propanol, iso-propanol and n-butanol, (E) ethyl acetate, (f) chloroform, (g) 1,3-butylene glycol, (h) hexane, (i) diethyl ether, or (iii) a mixed solvent of a lower alcohol and water. (j) The extract can be obtained by treating butyl acetate with rice doenjang.
본 명세서에서 사용되는 용어 “추출물”은 상술한 바와 같이 당업계에서 조추출물(crude extract)로 통용되는 의미를 갖지만, 광의적으로는 추출물을 추가적으로 분획(fractionation)한 분획물도 포함한다. 즉, 쌀된장 추출물은 상술한 추출용매를 이용하여 얻은 것뿐만 아니라, 여기에 정제과정을 추가적으로 적용하여 얻은 것도 포함한다. 예컨대, 상기 추출물을 일정한 분자량 컷-오프 값을 갖는 한외 여과막을 통과시켜 얻은 분획, 다양한 크로마토그래피 (크기, 전하, 소수성 또는 친화성에 따른 분리를 위해 제작된 것)에 의한 분리 등, 추가적으로 실시된 다양한 정제 방법을 통해 얻어진 분획도 본 발명의 쌀된장 추출물에 포함되는 것이다.As used herein, the term " extract " has the meaning conventionally used in the art as a crude extract, but broadly includes fractions obtained by further fractionation of the extract. That is, the rice doenjang extract includes not only those obtained by using the above-described extraction solvent but also those obtained by additionally applying a purification process thereto. For example, a fraction obtained by passing the above extract through an ultrafiltration membrane having a constant molecular weight cut-off value, and a separation by various chromatography (manufactured for separation according to size, charge, hydrophobicity or affinity) The fraction obtained through the purification method is also included in the rice doenjang extract of the present invention.
본 발명에서 이용되는 쌀된장 추출물은 감압 증류 및 동결 건조 또는 분무 건조 등과 같은 추가적인 과정에 의해 분말 상태로 제조될 수 있다.The rice doenjang extract used in the present invention can be prepared in powder form by an additional process such as vacuum distillation and freeze drying or spray drying.
택일적으로, 쌀된장 추출물로는, 쌀된장 자체를 동물에게 투여할 수 있도록 제형화(예컨대, 분말화)된 쌀된장 가공물이 이용될 수 있다. Alternatively, as the rice doenjang extract, a rice doenjang product that is formulated (for example, powdered) so that the rice bean itself can be administered to an animal can be used.
본 발명의 조성물이 약제학적 조성물로 제조되는 경우, 본 발명의 약제학적 조성물은 약제학적으로 허용되는 담체를 포함한다. 본 발명의 약제학적 조성물에 포함되는 약제학적으로 허용되는 담체는 제제 시에 통상적으로 이용되는 것으로서, 락토스, 덱스트로스, 수크로스, 솔비톨, 만니톨, 전분, 아카시아 고무, 인산 칼슘, 알기네이트, 젤라틴, 규산 칼슘, 미세결정성 셀룰로스, 폴리비닐피롤리돈, 셀룰로스, 물, 시럽, 메틸 셀룰로스, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 활석, 스테아르산 마그네슘 및 미네랄 오일 등을 포함하나, 이에 한정되는 것은 아니다. 본 발명의 약제학적 조성물은 상기 성분들 이외에 윤활제, 습윤제, 감미제, 향미제, 유화제, 현탁제, 보존제등을 추가로 포함할 수 있다. 적합한 약제학적으로 허용되는 담체 및 제제는 Remington's Pharmaceutical Sciences (19th ed., 1995)에 상세히 기재되어 있다.When the composition of the present invention is manufactured from a pharmaceutical composition, the pharmaceutical composition of the present invention includes a pharmaceutically acceptable carrier. The pharmaceutically acceptable carriers to be contained in the pharmaceutical composition of the present invention are those conventionally used in the formulation and include lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, But are not limited to, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrups, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. It is not. The pharmaceutical composition of the present invention may further contain a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, etc. in addition to the above components. Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington ' s Pharmaceutical Sciences (19th ed., 1995).
본 발명의 약제학적 조성물은 쥐, 생쥐, 가축, 인간 등의 포유동물에 경구 또는 비경구 등의 다양한 경로로 투여할 수 있으며, 예컨대 경구, 직장 또는 정맥, 근육, 피하, 자궁내 경막 또는 뇌혈관내 주사에 의해 투여할 수 있다. 바람직하게는 비경구 투여 중 경피투여, 보다 바람직하게는 도포에 의한 국부 투여(topical application) 방식으로 적용된다.The pharmaceutical composition of the present invention can be administered to mammals such as rats, mice, livestock, and humans in various routes such as oral or parenteral routes such as oral, rectal or intravenous, muscular, subcutaneous, intra-uterine, Can be administered by injection. Preferably, it is applied by transdermal administration during parenteral administration, more preferably by topical application by application.
본 발명의 약제학적 조성물의 적합한 투여량은 제제화 방법, 투여 방식, 환자의 연령, 체중, 성, 병적 상태, 음식, 투여 시간, 투여 경로, 배설 속도 및 반응 감응성과 같은 요인들에 의해 다양하게 처방될 수 있다. 본 발명의 약제학적 조성물의 투여량은, 경구형 제형인 경우 성인 기준으로 0.1-100 ㎎/kg 의 양을 1일 1회 내지 수회 투여할 수 있으며, 외용제인 경우에는 성인 기준으로 1일당 1.0 내지 3.0 ml의 양으로 1일 1 내지 5회 도포하여 1개월 이상 계속 하는 것이 좋다. 다만, 상기 투여량은 본 발명의 범위를 한정하는 것은 아니다.The appropriate dosage of the pharmaceutical composition of the present invention may vary depending on factors such as the formulation method, administration method, age, body weight, sex, pathological condition, food, administration time, administration route, excretion rate, . The dose of the pharmaceutical composition of the present invention can be administered in an amount of 0.1-100 mg / kg on an adult basis once or several times a day in the case of an oral formulation, and in the case of an external preparation, It is preferable to apply it once to 5 times a day in an amount of 3.0 ml and continue for 1 month or longer. However, the dosage is not intended to limit the scope of the present invention.
본 발명의 약제학적 조성물은 당해 발명이 속하는 기술분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있는 방법에 따라, 약제학적으로 허용되는 담체 및/또는 부형제를 이용하여 제제화함으로써 단위 용량 형태로 제조되거나 또는 다용량 용기 내에 내입시켜 제조될 수 있다. 이때 제형은 산제, 과립제, 정제, 캅셀제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 연고, 크림 등의 외용제, 좌제 및 멸균 주사용액 등을 비롯하여 약제학적 제제에 적합한 어떠한 형태로든 사용할 수 있으며, 분산제 또는 안정화제를 추가적으로 포함할 수 있다.
The pharmaceutical composition of the present invention may be formulated into a unit dose form by formulating it using a pharmaceutically acceptable carrier and / or excipient according to a method which can be easily carried out by a person having ordinary skill in the art to which the present invention belongs. Or by intrusion into a multi-dose container. The formulations may be in any form suitable for pharmaceutical preparations including oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups and aerosols, external preparations such as ointments and creams, suppositories and sterile injectable solutions, , Dispersants, or stabilizers.
본 발명의 바람직한 양태에 따르면, 본 발명의 조성물은 항암 효과가 탁월한 식품 조성물일 수 있다.According to a preferred embodiment of the present invention, the composition of the present invention may be a food composition having excellent anticancer effect.
본 발명의 조성물이 식품 조성물로 제조되는 경우, 유효성분뿐만 아니라, 식품 제조 시에 통상적으로 첨가되는 성분을 포함하며, 예를 들어, 단백질, 탄수화물, 지방, 영양소, 조미제 및 향미제를 포함한다. 상술한 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스, 올리고당 등; 및 폴리사카라이드, 예를 들어 덱스트린, 사이클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 향미제로서 천연 향미제 [타우마틴, 스테비아 추출물 (예를 들어 레바우디오시드 A, 글리시르히진 등]) 및 합성 향미제(사카린, 아스파르탐 등)를 사용할 수 있다.When the composition of the present invention is prepared with a food composition, it includes not only the active ingredient, but also ingredients normally added during the manufacture of the food, including, for example, proteins, carbohydrates, fats, nutrients, flavoring agents and flavoring agents . Examples of the above-mentioned carbohydrates are monosaccharides such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose, oligosaccharides and the like; And polysaccharides such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavorings such as tau martin and stevia extract (e.g., rebaudioside A and glycyrrhizin) and synthetic flavorings (saccharine, aspartame, etc.) can be used as flavorings.
예컨대, 본 발명의 식품 조성물이 드링크제로 제조되는 경우에는 본 발명의 유효성분 이외에 구연산, 액상과당, 설탕, 포도당, 초산, 사과산, 과즙, 두충 추출액, 대추 추출액, 감초 추출액 등을 추가로 포함시킬 수 있다.
For example, when the food composition of the present invention is prepared as a drink, it may further contain citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, juice, mulberry extract, jujube extract, licorice extract, have.
한편, 본 발명의 구체적 실시예에서 본 발명 조성물의 유효성분에 대한 세포 생존율 분석 결과 본 발명 조성물의 유효성분은 천연물질로서 인체에 무해한 물질임이 밝혀졌다. 따라서, 본 발명의 유효성분은 독성 및 부작용이 거의 없으므로 장기간 사용 시에도 안심하고 사용할 수 있으며, 특히 상기한 바와 같은 화장료, 약제학적 및 식품 조성물에 안전하게 적용할 수 있다.As a result of analyzing cell viability with respect to the active ingredient of the composition of the present invention in the concrete examples of the present invention, it was found that the active ingredient of the composition of the present invention is a harmless substance as a natural substance. Therefore, since the active ingredient of the present invention has little toxicity and side effects, it can be safely used even for long-term use, and can be safely applied to cosmetic, pharmaceutical and food compositions as described above.
본 발명의 특징 및 이점을 요약하면 다음과 같다: The features and advantages of the present invention are summarized as follows:
(ⅰ) 본 발명은 하기 단계를 포함하는 항암(抗癌) 활성을 나타내는 쌀된장 제조방법을 제공한다: (a) 증자(蒸煮)콩 및 쌀을 배합한 이후 미생물을 접종하는 단계: (b) 상기 단계 (a)의 미생물을 접종하여 배합한 증자콩 및 쌀을 이용하여 메주를 성형(成型)한 이후 숙성하는 단계: (c) 상기 단계(b)의 메주를 파쇄(破碎)하는 단계: 및 (d) 상기 단계(c)의 파쇄된 메주에 물 및 소금을 첨가한 이후 숙성하는 단계. (I) the present invention provides a method for preparing rice doenjang exhibiting anticancer activity comprising the steps of: (a) inoculating a microorganism after mixing with boiled soybeans and rice; (b) (C) aging the Meju of the step (b): (b) breaking down the Meju of the step (b); and (d) aging after adding water and salt to the crushed Meju of step (c).
(ⅱ) 본 발명의 방법으로 제조한 쌀된장의 경우 탁월한 항암 효과를 나타내는 장점을 제공한다.(Ii) Rice miso produced by the method of the present invention provides an advantage of showing excellent anticancer effect.
(ⅲ) 본 발명의 방법으로 제조한 쌀된장의 경우 기존 재래 된장과 비교하여, 유기산 등의 함량이 많을 뿐만 아니라, 제조 기간을 비약적으로 단축시킬 수 있는 장점을 제공한다.(Iii) In the case of rice doenjang prepared by the method of the present invention, the content of organic acid and the like is much higher than that of conventional doenjang, and the production period can be shortened remarkably.
도 1은 쌀메주 제형별 외형을 나타낸다.
도 2는 쌀메주 제형별 아미노태 질소 변화를 나타낸다.
도 3은 쌀메주 제형별 암모니아태 질소 변화를 나타낸다.
도 4는 쌀메주 제형별 환원당 변화를 나타낸다.
도 5는 쌀메주 제형별 프로테아제 활성 변화를 나타낸다.
도 6은 쌀메주 제형별 아밀라아제 활성 변화를 나타낸다.
도 7은 쌀된장의 숙성 기간에 따른 호기성 총 균수 변화를 나타낸다.
도 8은 쌀된장의 숙성 기간에 따른 유산균 수 변화를 나타낸다.
도 9는 쌀된장 추출물을 대장암 세포주(HT-29)에 처리하여 이후 MTT assay에 의해 그 항암 효과를 측정한 결과이다.
도 10은 쌀된장 추출물을 폐암 세포주(A-549)에 처리하여 이후 MTT assay에 의해 그 항암 효과를 측정한 결과이다.Fig. 1 shows the outline of rice meju type.
Fig. 2 shows changes in amino nitrogen of rice meju type.
Figure 3 shows the ammonia nitrogen change by rice meju formulation.
Fig. 4 shows the change in reducing sugar per rice meju type.
Figure 5 shows the change in protease activity of rice meju formulations.
6 shows changes in amylase activity of rice meju type.
Fig. 7 shows changes in aerobic total bacterial counts according to aging period of rice miso.
Fig. 8 shows changes in the number of lactic acid bacteria according to the ripening period of rice miso.
FIG. 9 shows the result of measuring the antitumor effect of MTT assay after treatment of rice doenjang extract with a colon cancer cell line (HT-29).
FIG. 10 shows the results of treating the lung cancer cell line (A-549) with rice doenjang extract and measuring its anti-cancer effect by MTT assay.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명 하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로서, 본 발명의 요지 따라 본 발명의 범위가 이들 실시예에 의해 제한되지 않는다는 것은 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자에게 있어서 자명할 것이다.
Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not to be construed as limiting the scope of the present invention. It will be self-evident.
실시예Example
본 명세서 전체에 걸쳐, 특정 물질의 농도를 나타내기 위하여 사용되는 “%“는 별도의 언급이 없는 경우, 고체/고체는 (중량/중량) %, 고체/액체는 (중량/부피) %, 그리고 액체/액체는 (부피/부피) %이다.
Throughout this specification, "%" used to denote the concentration of a particular substance is intended to include solids / solids (wt / wt), solid / liquid (wt / The liquid / liquid is (vol / vol)%.
실시예 1 : 쌀된장의 재료 및 제조 방법Example 1: Materials and preparation method of rice doenjang
실시예 1-1 : 제형별 쌀된장 메주 제조Example 1-1: Preparation of rice miso meju by formulation
콩은 24시간 수침 후, 고압멸균기(121℃, 40min)를 이용하여 증자하고 마쇄하였다. 전통 장류 및 메주에서 분리한 Bacillus subtillis HJ18-4(KACC91541P) 및 Aspergillus oryzae(KACC40250)을 스타터(Starter)로 사용하였으며, 찐 콩과 쌀의 배합 비율을 3:2로 하여, 흩임 메주, 디스크(Disc)형 메주 및 일반 육면체 메주로 제형을 달리하여 메주를 성형한 후, 양지에서 하루 동안 겉 말림하고, 14일 동안 28℃에서 메주를 띄웠다. 표 1에는 본 실험에서의 대조군 및 실험군의 처리 내용이 상세히 기재되어 있으며, 도 1에는 본 실험에서 제조한 쌀메주들의 제형별 외형이 나타나 있다. 이후 완성된 메주를 파쇄 하여 물과 10% 소금을 첨가하여 저염으로 제조하여 숙성시켰다. 제조된 날을 0일째로 하여 7일 간격으로 시료를 채취하여 분석 시료로 사용하였다.
The soybeans were soaked for 24 hours and then baked and sterilized using a high-pressure sterilizer (121 ° C, 40 min). Bacillus subtillis HJ18-4 (KACC91541P) and Aspergillus oryzae (KACC40250) were used as starter, and the ratio of steamed soybean to rice was 3: 2. ) Type meju and a normal hexahedral meju, the meju was molded, and the meju was outcropped in sunny day for 14 days at 28 ° C. Table 1 shows details of the treatments of the control group and the experimental group in this experiment, and Fig. 1 shows the appearance of the rice meju prepared in this experiment. After that, the finished meju was crushed, and water and 10% salt were added to produce low salt and aged. Samples were collected at intervals of 7 days on the
쌀 : MD05Rice: MD05
개별 접종, 발효Individual inoculation, fermentation
(400 g, 12 (400 g, 12
cmcm
*3 * 3
cmcm
))
(400 g, 12 (400 g, 12
cmcm
*3 * 3
cmcm
))
(28 내지 30℃ 습도 70 내지 80%) (28 to < RTI ID = 0.0 > 30 C &
콩코지Bean kochi
: 60 : 60
hrhr
쌀코지Rice koji
: 6일: 6 days
(28 내지 30℃, 습도 70 내지 80%) (28 to 30 DEG C, humidity: 70 to 80%).
(28 내지 30℃, 습도 70 내지 80%) (28 to 30 DEG C, humidity: 70 to 80%).
(28 내지 30℃, 습도 70 내지 80%) (28 to 30 DEG C, humidity: 70 to 80%).
총 중량의 10% 소금첨가10% of total weight added
실시예Example 1-2 : 1-2: 쌀된장Rice miso 추출물 제조 Extract preparation
쌀된장 추출물은 시료 20 g에 증류수 80 mL을 넣고 균질화 한 후, 이를 원심분리(8,000 rpm, 10min)하여 상등액을 시료 추출액으로 사용하였다.
For the rice doenjang extract, 80 mL of distilled water was added to 20 g of the sample, homogenized, and centrifuged (8,000 rpm, 10 min) to use the supernatant as the sample extract.
실시예Example 2 : 2 : 쌀된장의Rice miso 분석 analysis
실시예Example 2-1 : 2-1: 아미노태Amino acid 질소 함량 측정 Nitrogen content measurement
본 실험에서 제조한 쌀된장의 아미노태 질소 함량은 시료 추출액 5 mL, 중성 포르말린(Formalin) 용액 10 mL 및 증류수 10 mL을 넣은 플라스크에 0.5% 페놀프탈레인(Phenolphthalein) 용액을 2 내지 3방울 가한 후, 0.1 N NaOH로 미홍색이 될 때까지의 적정량과 시료 5 mL 및 증류수 20 mL을 넣은 플라스크에 0.5% 페놀프탈레인 용액을 2 내지 3방울 가한 후, 0.1 N NaOH로 미홍색이 될 때까지의 적정량을 이용하여 아미노태 질소 함량을 산출하였다(Choi HS, Joo SJ, Yoon HS, Kim KS, Song IG, Min KB. Quality characteristics of hwangki(Astragalus membranaceus) cheong-gukjang during fermentation. Korean J. Food Preserv. 14: 356-363(2007) ).
Amino nitrogen content of rice doenjang prepared in this experiment was determined by adding 2 ~ 3 drops of 0.5% phenolphthalein solution to a flask containing 5 mL of sample extract, 10 mL of formalin solution and 10 mL of distilled water, Add 2 to 3 drops of a 0.5% phenolphthalein solution to a flask containing 5 mL of sample and 20 mL of distilled water, add the appropriate amount until it turns to a red color with N NaOH, add the solution with 0.1 N NaOH The amino acid nitrogen content was calculated by the following formula (Choi HS, Joo SJ, Yoon HS, Kim KS, Song IG, and Min KB, Quality properties of hwangki (Astragalus membranaceus) 363 (2007)).
실시예Example 2-2 : 암모니아태 질소 함량 측정 2-2: Determination of ammonia nitrogen content
본 실험에서 제조한 쌀된장의 암모니아태 질소 함량은 페놀-하이포아염소산염(Phenol-hypochloride) 반응에 의하여 시료 추출액 0.1 mL에 A용액(Phenol 10 g과 Sodium nitroprusside dihydrate 0.05 g/distilled water 1 L)과 B용액(Na2HPO412H2O 9 g, NaOH 6 g과 NaOCl 10 mL/distilled water 1 L)을 각각 2 mL씩 넣고 37℃에서 20분간 반응시켜 630 nm에서 흡광도를 측정하였으며, 황산 암모늄(Ammonium sulfate)을 이용하여 표준곡선을 토대로 암모니아태 질소량을 계산하였다(Hwang HA, Lee NK, Cho IJ, Hahm YT, Kwon KO, Kim BY. 2008. Selection of microorganism and optimization of manufacture process for cheonggukjang. Korean J Food Sci Technol 40: 406-411.).
The ammonia nitrogen content of rice doenjang prepared in this experiment was determined by adding phenol-hypochloride reaction to 0.1 mL of sample solution (10 g of phenol and 0.05 g of sodium nitroprusside dihydrate / 1 L of distilled water) B solution (9 g of Na2HPO412H2O, 6 g of NaOH and 1 L of NaOCl 10 mL / distilled water) was added to each well and incubated at 37 ° C for 20 minutes. The absorbance at 630 nm was measured using Ammonium sulfate (Hwang HA, Lee NK, Cho IJ, Hahm YT, Kwon KO, Kim BY 2008. Selection of microorganism and optimization process for cheonggukjang J Food Sci Technol 40: 406 -411.).
실시예Example 2-3 : 환원당 측정 2-3: Measurement of reducing sugar
된장의 환원당 함량은 디니트로살리실산 법(Dinitrosalicylic acid methid, DNS 법)(Miller, G. L. 1960. Measurement of carboxymethyl cellulose activity. Anal. Biochem. 2, 127-132.)으로 측정하였다. 시험관에 DNS 시약 3 mL과 희석한 시료용액 1 mL을 가하고 진탕한 후 끓는 수조에서 정확히 3분간 방치하고 즉시 얼음수조에서 냉각시킨 다음 550 nm에서 흡광도를 측정하고 표준곡선으로부터 환원당 함량을 산출하였다.
The reducing sugar content of doenjang was measured by the dinitrosalicylic acid methid (DNS method) (Miller, GL 1960. Measurement of carboxymethyl cellulose activity, Anal. Biochem., 2, 127-132). 3 mL of the DNS reagent and 1 mL of the diluted sample solution were added to the test tube, shaken and allowed to stand in a boiling water bath for 3 minutes, immediately cooled in an ice water bath, and the absorbance was measured at 550 nm and the reducing sugar content was calculated from the standard curve.
실시예Example 2-4 : 2-4: ProteaseProtease 활성 측정 Active measurement
프로테아제(Protease)의 활성도는 Anson의 방법을 변형하여 측정하였다(Kim HJ, Lee JJ, Cheigh MJ, Choi SY. 1998. Amylase, protease, peroxidase and ascorbic acid oxidase activity of Kimchi ingredients. Korean J Food Sci Technol 30: 1333-1338.). 즉, 시료 추출액 1 mL과 0.6% 카세인(Casein) 기질용액(0.2 M phosphate buffer, pH 7.0)을 넣고 37°C에서 10분간 반응시켰다. 반응 후 0.44 M 트라이클로로아세트산(Trichloroacetic acid, TCA) 5 mL을 넣어 반응을 중지시켰다. 실온에서 30분간 방치한 다음 No.2 여과지에 여과한 여액 2 mL에 0.55 M Na2CO3용액 5 mL과 3배 희석된 폴린 시약(Folin reagent) 용액 1 mL을 넣어 실온에서 30 분간 반응시킨 후, 660 nm에서 흡광도를 측정하였다. 이 반응조건 하에서 1분간에 타이로신(Tyrosine) 1 μg을 유리시키는 효소량을 1 unit으로 하였다
The activity of protease was measured by modifying Anson's method (Kim HJ, Lee JJ, Cheigh MJ, Choi SY, 1998. Amylase, protease, peroxidase and ascorbic acid oxidase activity of Kimchi ingredients. : 1333-1338.). That is, 1 mL of the sample extract and 0.6% casein substrate solution (0.2 M phosphate buffer, pH 7.0) were added and reacted at 37 ° C for 10 minutes. After the reaction, 5 mL of 0.44 M trichloroacetic acid (TCA) was added to terminate the reaction. After allowing to stand at room temperature for 30 minutes, 5 mL of 0.55
실시예Example 2-5 : α- 2-5: α- amylaseamylase 활성 측정 Active measurement
α-Amylase 활성 측정은 1% 가용성전분(0.02 M phosphate buffer, pH 7.0) 3 mL에 시료 추출액 1 mL 첨가하여 40℃에서 10분간 반응시킨 후, 1 M HCl 10 mL을 넣어 반응을 중지시켰다. 요오드화 용액(0.005% I2+0.05% KI) 10 mL을 넣고 발색시킨 후 660 nm에서 흡광도를 측정하였다. 대조구 OD값을 10% 감소시키는 것을 1 unit으로 하여 시료 1 g으로 환산시킨 후 표시하였다(Park JM, Oh HI. 1995. Changes in microflora and enzyme activities of traditional Kochujang Meju during fermentation. Korean J Food Sci Technol 27: 1158-1165.).
The α-Amylase activity was measured by adding 1 mL of the sample extract to 3 mL of 1% soluble starch (0.02 M phosphate buffer, pH 7.0), reacting at 40 ° C for 10 minutes, and then stopping the reaction by adding 10 mL of 1 M HCl. Iodination solution (0.005% I2 + 0.05% KI) was added to 10 mL of the solution and developed. The absorbance at 660 nm was measured. The results are shown in Table 1. The results are shown in Table 1. The results are shown in Table 1. The results are shown in Table 1. The results are shown in Table 1. : 1158-1165.).
실시예Example 2-6 : 총 2-6: Total 균수Number of bacteria 측정 Measure
총 균수 측정은 Plate count agar(Difco, Sparks, MD, USA)에 각 시료의 단계적 희석 액을 도말하여 배양(37℃, 24 hr) 한 후, 결과를 계수하여 측정하였다.
The total number of bacterial counts was determined by counting the results after culturing (37 ° C, 24 hr) with plate dilution of each sample in a plate count agar (Difco, Sparks, MD, USA).
실시예Example 2-7 : 2-7: 유산균수Number of lactic acid bacteria 측정 Measure
유산균수 측정은 MRS agar(Difco, Sparks, MD, USA)에 각 시료의 단계적 희석액을 도말하여 배양(37℃, 48 hr) 한 후, 결과를 계수하여 측정하였다.
The number of lactic acid bacteria was measured by counting the results after culturing (37 ° C, 48 hr) by streaking a stepwise dilution of each sample in MRS agar (Difco, Sparks, MD, USA).
실시예Example 2-8 : 항암활성 2-8: Antitumor activity
대장암 (HT-29 : KCLB 30038) 및 폐암(A-549 : KCLB-10185) 세포주를 96 well plate에 1×104/well이 되게 분주한 후, 쌀된장 추출물(0.04%)을 처리하여 배양(37℃, 48 hour)한 후, MTT assay 하여 세포생존율을 측정하여 항암 활성을 확인하였다.
The cells were cultured in 96-well plates at a density of 1 × 10 4 cells / well, followed by treatment with rice doenjang extract (0.04%), followed by incubation with culture medium (HT-29; KCLB 30038) and lung cancer (A-549; KCLB-10185) (37 ° C, 48 hours), MTT assay was performed to determine the cell survival rate.
실시예Example 3 : 실험 결과 3: Experimental results
실시예Example 3-1 : 3-1: 쌀메주Rice meju 제형별 By formulation 아미노태Amino acid 질소 변화 Nitrogen change
도 2는 쌀메주 제형별 아미노태 질소 변화를 나타낸다. Rice 3이 21일까지 아미노태 질소가 급격히 증가하여 약 200 mg%에 도달한 이후 정체를 보였으며, Rice 2가 두 번째로 빠르게 증가하였다. Control과 Rice 1은 아미노태 질소가 상대적으로 느리게 증가하였다.
Fig. 2 shows changes in amino nitrogen of rice meju type.
실시예Example 3-2 : 3-2: 쌀메주Rice meju 제형별 암모니아태 질소 변화 Ammonia nitrogen change by formulation
도 3은 쌀메주 제형별 암모니아태 질소 변화를 나타낸다. Rice 1이 암모니아태 질소가 가장 빠르게 증가하였으며, Rice 3, Control 및 Rice 2의 순으로 암모니아태 질소 증가 속도가 빨랐다.
Figure 3 shows the ammonia nitrogen change by rice meju formulation.
실시예Example 3-3 : 3-3: 쌀메주Rice meju 제형별 환원당 변화 Reducing sugar change by formulation
도 4는 쌀메주 제형별 환원당 변화를 나타낸다. 환원당의 변화는 실험군 별 큰 차이가 없었으며, 발효가 진행됨에 따라 증가하는 경향을 보였다.
Fig. 4 shows the change in reducing sugar per rice meju type. There was no significant difference in reducing sugar content between the experimental groups, and the tendency was increased as the fermentation progressed.
실시예Example 3-4 : 3-4: 쌀메주Rice meju 제형별 프로테아제 활성 변화 Protease activity changes by formulation
도 5는 쌀메주 제형별 프로테아제 활성 변화를 나타낸다. Rice 2와 Rice 3이 비슷한 속도로 빠르게 증가하였으며, Rice 1은 매우 완만하게 증가하였다.
Figure 5 shows the change in protease activity of rice meju formulations.
실시예Example 3-5 : 3-5: 쌀메주Rice meju 제형별 By formulation 아밀라아제Amylase 활성 변화 Activity change
도 6은 쌀메주 제형별 아밀라아제 활성 변화를 나타낸다. Rice 2와 Rice 3은 발효초반에 높은 활성(300 unit/g이상)을 나타내었으며, 이후 완만하게 활성이 증가하였다. Control과 Rice 1은 발효기간 내내 상대적으로 완만하게 활성도가 증가하였다.
6 shows changes in amylase activity of rice meju type.
실시예Example 3-6 : 3-6: 쌀된장의Rice miso 숙성 기간에 따른 호기성 총 Aerobic gun according to aging period 균수Number of bacteria 변화 change
도 7은 쌀된장의 숙성 기간에 따른 호기성 총 균수 변화를 나타낸다. 0일부터 42일까지 대체적으로 큰 변화 없이 일정하였으며, Rice 1이 가장 많은 호기성 총 균수를 나타냈다.
Fig. 7 shows changes in aerobic total bacterial counts according to aging period of rice miso.
실시예Example 3-7 : 3-7: 쌀된장의Rice miso 숙성 기간에 따른 유산균 수 변화 Changes in the Number of Lactic Acid Bacteria by Aging Period
도 8은 쌀된장의 숙성 기간에 따른 유산균 수 변화를 나타낸다. 모든 실험군에서 발효가 진행됨에 따라 유산균수가 감소하는 경향을 보였으며, 42일 숙성 후, Control 과 Rice 1에서의 유산균수가 다른 두 실험군에 비하여 상대적으로 많았다.
Fig. 8 shows changes in the number of lactic acid bacteria according to the ripening period of rice miso. As fermentation progressed in all experimental groups, the number of lactic acid bacteria tended to decrease. After 42 days of fermentation, the number of lactic acid bacteria in Control and
실시예Example 3-8 : 3-8: 쌀된장의Rice miso 대장암 및 폐암 성장 저해 효과 Inhibition of colon cancer and lung cancer growth
도 9는 쌀된장 추출물을 대장암 세포주(HT-29)에 처리하여 이후 MTT assay에 의해 그 항암 효과를 측정한 결과이다. 쌀된장 추출물을 대장암 세포주(HT-29)에 처리하여 항암 효과를 분석해 본 결과, 스타터를 첨가하지 않은 RSP-Con.이 67.32%의 생장을 보인데 비하여 RSP-1이 47.59%, RSP-2가 42.98% 및 RSP-3가 47.48%의 생장정도를 보였다.FIG. 9 shows the result of measuring the antitumor effect of MTT assay after treatment of rice doenjang extract with a colon cancer cell line (HT-29). RSP-1 (47.59%) and RSP-2 (67.32%) showed the growth of 67.32% of RSP-Con without addition of starter, And RSP-3 showed a growth rate of 47.48% and 42.98%, respectively.
도 10은 쌀된장 추출물을 폐암 세포주(A-549)에 처리하여 이후 MTT assay에 의해 그 항암 효과를 측정한 결과이다. 쌀된장 추출물을 폐암 세포주(A-549)에 처리하여 항암 효과를 분석해 본 결과, 스타터를 첨가하지 않은 RSP-Con.이 78.67%의 생장을 보인데 비하여 RSP-1이 51.78%, RSP-2가 39.61% 및 RSP-3이 56.51%의 생장정도를 보였다.FIG. 10 shows the results of treating the lung cancer cell line (A-549) with rice doenjang extract and measuring its antitumor effect by MTT assay. RSP-1, RSP-1, RSP-1, and RSP-2 showed the highest growth rate of 78.67%, respectively. 39.61% and RSP-3 showed a growth rate of 56.51%.
상기의 결과들은 본 실험에 사용한 Bacillus sp.균 및 Aspergillus sp.의 접종으로 인한 균체유래 다양한 유용 대사산물에 의한 항암 효과의 결과로 사료되었다.
The above results are considered to be the result of anticancer effects of various useful metabolites derived from cells by the inoculation of Bacillus sp. And Aspergillus sp.
실시예Example 3-9 : 3-9: 쌀된장의Rice miso 유기산 조성 및 함량 Organic acid composition and content
표 2는 쌀된장의 유기산 조성 및 함량을 분석한 결과이다. 유기산을 분석한 결과 citric, lactic, succinic, fumaric, malic acid가 동정 되었다. 이들 유기산 중 citric acid 및 lactic acid의 함량이 각각 1190.1 mg/kg, 517.28 mg/kg순으로 가장 높았다. 발효에 의한 유기산은 장류에 좋은 풍미를 준다.
Table 2 shows the results of analysis of organic acid composition and content of rice doenjang. Citric, lactic, succinic, fumaric and malic acid were identified by organic acid analysis. The contents of citric acid and lactic acid were 1190.1 mg / kg and 517.28 mg / kg, respectively. Organic acid by fermentation gives good flavor to the soup.
실시예Example 3-10 : 3-10: 쌀된장의Rice miso 아미노산 조성 및 함량 Amino acid composition and content
표 3은 쌀된장의 아미노산 조성 및 함량을 분석한 결과이다. 유리아미노산 분석 결과 glutamic acid 및 aspartic acid가 2,307 mg/100g, 1,577 mg/100g으로 함량이 가장 높았으며, leucine, lysine, valine 등의 순으로 함유되어 있었다. 유리아미노산은 된장의 맛을 좌우하게 되는데, 담금 원료, 숙성온도, 숙성 기간에 따라 차이가 있으며, 재래된장에서 맛에 대한 기여도는 leucine과 isoleucine 같은 쓴맛 성분이 가장 큰 영향을 미치며, 다음으로 cystine, aspartic acid, glutamic acid와 같은 구수한 맛 성분이 영향을 미친다고 알려져 있다.
Table 3 shows the analysis of amino acid composition and content of rice doenjang. Free amino acid analysis showed that glutamic acid and aspartic acid were the highest contents in the order of 2,307 mg / 100g and 1,577 mg / 100g, and were contained in order of leucine, lysine and valine. Free amino acids affect flavor of doenjang, which depends on fermented raw materials, fermentation temperature, and fermentation period. The contribution of flavor to traditional soybean paste is most affected by bitter components such as leucine and isoleucine, followed by cystine, Aspartic acid and glutamic acid are known to affect the taste components.
Claims (13)
(a) 콩을 각각 1-48 시간 수침(水浸)한 이후 고압멸균기(autoclave)를 이용하여 증자하고, 마쇄(磨碎) 처리하여 증자콩을 만드는 단계;
(b) 상기 증자콩에는 바실러스 서브틸러스 HJ18-4(KACC91541P)를 접종하고, 쌀에는 아스퍼질러스 오리재를 접종하는 단계;
(c) 상기 (b)단계를 거친 쌀과 증자콩을 부피기준 1: 1~1.5의 비율로 배합하는 단계;
(d) 상기 (c)단계의 쌀과 증자콩 배합물을 이용하여 메주를 성형(成型)한 이후 숙성하는 단계;
(e) 상기 단계(d)의 메주를 파쇄(破碎)하는 단계; 및
(f) 상기 단계(d)의 파쇄된 메주에 물 및 소금을 첨가한 이후 숙성하는 단계.
A method for preparing rice doenjang exhibiting anti-cancer activity comprising the steps of:
(a) soaking the soybeans for 1 to 48 hours each time, then using a high pressure autoclave to polish and polish the beans;
(b) inoculating Bacillus subtilis HJ18-4 (KACC91541P) to the expanded beans and inoculating the rice with aspergillus duck material;
(c) blending the rice and the expanded soybeans obtained in the step (b) at a ratio of 1: 1 to 1.5 by volume;
(d) aging the meju after molding the meju using the rice and the soybean mixture of step (c);
(e) crushing Meju of step (d); And
(f) adding water and salt to the crushed meju of step (d) and then aging.
상기 고압멸균기의 온도 조건은 80-150℃이고, 처리 시간은 1-120분인 것을 특징으로 하는 쌀된장 제조방법.
The method according to claim 1,
Wherein the high-pressure sterilizer has a temperature of 80-150 ° C and a treatment time of 1-120 minutes.
상기 단계 (b)의 성형시 성형 형상은 무형상(낱알 메주), 육면체 형상 또는 디스크 형상인 것을 특징으로 하는 쌀된장 제조방법.
The method according to claim 1,
Wherein the forming shape of the step (b) in the step (b) is an intangible (grains), a hexahedron, or a disk.
상기 단계 (b)의 숙성시 숙성 기간은 1-30일이고, 숙성 온도는 25-35℃이며, 숙성 상대 습도는 60-90%인 것을 특징으로 하는 쌀된장 제조방법.
The method according to claim 1,
Wherein the aging period of the step (b) is 1-30 days, the aging temperature is 25-35 ° C, and the aging relative humidity is 60-90%.
상기 단계 (d)의 소금 및 물의 중량기준 배합 비율은 1:5-10인 것을 특징으로 하는 쌀된장 제조방법.
The method according to claim 1,
Wherein the mixing ratio of salt and water in step (d) is 1: 5-10.
상기 단계 (d)의 숙성시 숙성 기간은 1-60일인 것을 특징으로 하는 쌀된장 제조방법.
The method according to claim 1,
Wherein the aging period of the step (d) is from 1 to 60 days.
상기 단계 (d)의 숙성시 숙성 기간은 35-45일인 것을 특징으로 하는 쌀된장 제조방법.
11. The method of claim 10,
Wherein the aging time of the step (d) is 35-45 days.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120068425A KR101459613B1 (en) | 2012-06-26 | 2012-06-26 | Soybean Paste and Manufacturing Method There of |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120068425A KR101459613B1 (en) | 2012-06-26 | 2012-06-26 | Soybean Paste and Manufacturing Method There of |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20140003726A KR20140003726A (en) | 2014-01-10 |
KR101459613B1 true KR101459613B1 (en) | 2014-11-13 |
Family
ID=50140030
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020120068425A KR101459613B1 (en) | 2012-06-26 | 2012-06-26 | Soybean Paste and Manufacturing Method There of |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101459613B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190064810A (en) | 2017-12-01 | 2019-06-11 | 강진된장영농조합법인 | Composition for Law-salted Soybean Paste Using Rice and Manufacturing Method the Same |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102322228B1 (en) | 2014-11-20 | 2021-11-08 | 삼성디스플레이 주식회사 | Touch screen panel and method of manufacturing the same |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100661707B1 (en) * | 2005-07-25 | 2006-12-26 | 장해춘 | DJI Method for preparing reduced off-flavor Doenjangsoybean paste composed of 100% soybean using Bacillus subtilis DJI |
KR20100008528A (en) * | 2008-07-16 | 2010-01-26 | 순창군 | Process for preparing fermented rice-soybean paste |
-
2012
- 2012-06-26 KR KR1020120068425A patent/KR101459613B1/en active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100661707B1 (en) * | 2005-07-25 | 2006-12-26 | 장해춘 | DJI Method for preparing reduced off-flavor Doenjangsoybean paste composed of 100% soybean using Bacillus subtilis DJI |
KR20100008528A (en) * | 2008-07-16 | 2010-01-26 | 순창군 | Process for preparing fermented rice-soybean paste |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190064810A (en) | 2017-12-01 | 2019-06-11 | 강진된장영농조합법인 | Composition for Law-salted Soybean Paste Using Rice and Manufacturing Method the Same |
Also Published As
Publication number | Publication date |
---|---|
KR20140003726A (en) | 2014-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101381112B1 (en) | Preparation method for fermented rhodiola rosea using red ginseng and composition for fatigue recovery and improvement of exercise performance comprising the fermented rhodiola rosea | |
KR100773125B1 (en) | Manufacturing Method for Meju increased ?-Aminobutyric acid content | |
KR101690197B1 (en) | Method for producing fermented Sparassis crispa extracts with enhanced free amino acid content | |
KR101402031B1 (en) | Method for producing fermented herb extract with high GABA content using Lactobacillus plantarum K154 | |
KR101705548B1 (en) | Composition for enhancing immune response comprising extract of Apios americana Medikus or fermented extract of the same | |
JP2005000161A (en) | Fermentation composition of cayenne pepper or capsaicinoid-containing plant | |
KR101338527B1 (en) | Reduction of biogenic amines in the fermented food by the plants extracts | |
KR101062172B1 (en) | Anti-cancer health food containing mushroom fermented ginseng powder | |
KR101296995B1 (en) | Fermented product comprising fermented rice bran and rice germ by lactobacillus and preparation method thereof | |
KR101459613B1 (en) | Soybean Paste and Manufacturing Method There of | |
KR20060111093A (en) | Manufacturing method of old red platycodon, old red platycodon and functional food | |
KR101091833B1 (en) | Methods for preparing high quantity of S-allyl-L-cysteine to fermented products of garlic using lactic acid bacteria | |
KR101871169B1 (en) | New kimchi lactic acid bacteria Weissella cibaria MFST and composition using concentrated extract of Ziziphus jujuba seed | |
JP5571650B2 (en) | Drugs for non-alcoholic fatty liver disease and / or non-alcoholic steatohepatitis | |
KR20150139198A (en) | Manufacturing Method for Mung Bean Sikhae | |
CN114588248B (en) | Composition for preventing and treating alcohol cancer and preparation method thereof | |
CN114304618B (en) | Method for enriching dandelion root active ingredients through fermentation and application of method | |
KR101310648B1 (en) | Composition comprising leaves of peucedanum japonicum for relieving hangover or fermented liquor having leaves of peucedanum japonicum | |
KR100742269B1 (en) | High functional soybean malt, soybean sauce and granule using it | |
KR20220098594A (en) | Composition for preventing, improving or treating atopic or allergic dermatitis comprising deer antler fermentation products as an active ingredient | |
KR101338526B1 (en) | Reduction of biogenic amines in the fermented food by the plants extracts | |
KR101219683B1 (en) | Composition with tyrosinase inhibition activity of grain Koji fermented with Aspergillus oryzae and Astragali Radix and method thereof | |
KR101668153B1 (en) | Law Sodium Soybean Paste and Soybean Paste Powder and Soybean Paste Pill Comprising Polyphenol and Manufacturing Method There of | |
JP4464082B2 (en) | Muscle cell sugar transport enhancing composition containing mugwort as an active ingredient | |
KR102487461B1 (en) | Solid fermented placenta, its use and manufacturing method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
X701 | Decision to grant (after re-examination) | ||
GRNT | Written decision to grant |